Related references
Note: Only part of the references are listed.Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Zunyou Wu et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad
Sandra Amor et al.
ANNALS OF NEUROLOGY (2020)
Immunology of COVID-19: Current State of the Science
Nicolas Vabret et al.
IMMUNITY (2020)
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
Safiya Richardson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
COVID-19 illness in native and immunosuppressed states: A clinical?therapeutic staging proposal
Hasan K. Siddiqi et al.
JOURNAL OF HEART AND LUNG TRANSPLANTATION (2020)
Estimating the burden of SARS-CoV-2 in France
Henrik Salje et al.
SCIENCE (2020)
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta et al.
LANCET (2020)
Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic
Lorenzo D'Antiga
LIVER TRANSPLANTATION (2020)
The COVID-19 pandemic and the use of MS disease-modifying therapies
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic
Wallace Brownlee et al.
NEUROLOGY (2020)
Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover
Annarosa Soresina et al.
PEDIATRIC ALLERGY AND IMMUNOLOGY (2020)
COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases
D. Baker et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)
Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination
Crystal Zheng et al.
CNS DRUGS (2020)
Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis
Celine Louapre et al.
JAMA NEUROLOGY (2020)
Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study
Andrew Clark et al.
LANCET GLOBAL HEALTH (2020)
Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab
Kulachanya Suwanwongse et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19
Gavin Giovannoni
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic
David Baker et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran
Farinaz Safavi et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic
Mahsa Ghajarzadeh et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain
Paloma Montero-Escribano et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series
Richard Hughes et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?
Giovanni Novi et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach
Sherif M. Hamdy et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2020)
COVID-19 outcomes in MS Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center
Erica Parrotta et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)
COVID-19 in multiple sclerosis: The Dutch experience
Floor C. Loonstra et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
COVID-19 in people with multiple sclerosis: A global data sharing initiative
Liesbet M. Peeters et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient
Hannah Wurm et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Factors associated with COVID-19-related death using OpenSAFELY
Elizabeth J. Williamson et al.
NATURE (2020)
Neurological immunotherapy in the era of COVID-19-looking for consensus in the literature
Catharina Korsukewitz et al.
NATURE REVIEWS NEUROLOGY (2020)
Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection?
Mahsa Ghajarzadeh et al.
NEUROLOGICAL SCIENCES (2020)
Five years of ocrelizumab in relapsing multiple sclerosis OPERA studies open-label extension
Stephen L. Hauser et al.
NEUROLOGY (2020)
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis The VELOCE study
Amit Bar-Or et al.
NEUROLOGY (2020)
Vaccination in B-cell-depleted patients with multiple sclerosis
Joep Killestein et al.
NEUROLOGY (2020)
Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters
John P. A. Ioannidis et al.
ENVIRONMENTAL RESEARCH (2020)
Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins
Jose Maria Diez et al.
IMMUNOTHERAPY (2020)
Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China
Fan Wu et al.
JAMA INTERNAL MEDICINE (2020)
COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies
Virginia Meca-Lallana et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia
William L. Conte
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
Matteo Lucchini et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Negative SARS-CoV-2 antibody testing following COVID-19 infection in Two MS patients treated with ocrelizumab
Jeanine Rempe Thornton et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Factors Associated with Prescribing Oral Disease Modifying Agents in Multiple Sclerosis: a Real-world Analysis of Electronic Medical Records
Jagadeswara R. Earla et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab
Marco Iannetta et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Risk Factors for Mortality in Hospitalized Patients with COVID-19: An Overview in a Mexican Population
Arturo Cortes-Telles et al.
TUBERCULOSIS AND RESPIRATORY DISEASES (2020)
The trinity of COVID-19: immunity, inflammation and intervention
Matthew Zirui Tay et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Validation of an algorithm for identifying MS cases in administrative health claims datasets
William J. Culpepper et al.
NEUROLOGY (2019)
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
S. L. Hauser et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Share Paper
